Debt Investors

Home / Investor relations / Debt Investors

Funding strategy

  • The Board reviews the Company’s ongoing liquidity risks annually as part of the planning process and on an ad-hoc basis.
  • The Board considers short-term requirements against available sources of funding, taking into account forecast cash flows.
  • The Company manages liquidity risk by maintaining access to a number of sources of funding which are sufficient to meet anticipated funding requirements.
  • Specifically, the Company uses US commercial paper and/or Euro-commercial paper programmes, committed bank facilities and cash resources to manage short-term liquidity.
  • The Company maintains strong access to the capital markets for long-term funding through an established Euro Medium Term Note (EMTN) programme and a SEC registered shelf programme.
  • The Company also has access to Term Loans provided by the Group’s relationship banks. At 30 June 2024, $2bn of loans were outstanding in respect of funding the acquisition of Alexion Pharmaceutical, Inc.. These were repaid during July 2024.
  • The Company has $6.9bn of revolving committed credit facilities provided by 13 relationship banks. These facilities were undrawn as at 30 June 2024. $2bn will mature in February 2025 and $4.9bn in April 2029.
  • These different funding programmes ensure that the Company has sufficient flexibility when choosing the maturity, currency, interest rate (fixed/floating), and geographical mix of investors.

 

Programme Last updated Valid to Limit Rating (Moody's/ S&P) Utilisation as at 30 June 2024

US Commercial Paper

N/A

N/A

USD 15bn

A-1 / P-1

USD 2.5bn

Euro-Commercial Paper

12 May 2020

N/A

EUR 10bn

Issuer rating

None

Euro Medium Term Note Programme

June 2024

June 2025

USD 10bn

A2 / A+

USD 3.8bn

SEC Shelf Registration Statement

Mar 2024

Mar 2027

Unlimited

A2 / A+

USD 23.5bn

Debt maturity profile

AstraZeneca chooses to hold a significant cash balance to meet operational funding needs. Gross cash and investments position as at 30 June 2024 was $7.1bn

1  Notional bond values. FX converted at 30 June 2024 spot rates (USD/EUR 0.935; USD/GBP 0.791). Current portion of leases of $292m are included in 2024, whilst non-current Leases of $949m have been excluded from the chart.

Outstanding bonds

Below is a summary of the bonds issued or guaranteed by AstraZeneca PLC as at 30 June 2024, sorted by maturity date.

Issuer Currency Notional (m) Issue date Maturity date Coupon Frequency ISIN Note

AZ PLC

USD 2,000 16-Nov-15 16-Nov-25 3.375% Semi-annual US046353AL27  

AZ PLC

USD 1,200 06-Aug-20 08-Apr-26 0.70% Semi-annual US046353AV09  

AZ Finance LLC

USD 1,250 28-May-21 28-May-26 1.20% Semi-annual US04636NAA19  

AZ Finance LLC

USD 1,250 26-Feb-24 26-Feb-27 4.80% Semi-annual US04636NAK90  

AZ PLC

EUR 750 03-Mar-23 03-Mar-27 3.625% Annual XS2593105393 1

AZ PLC

USD 750 12-Jun-17 12-Jun-27 3.125% Semi-annual US046353AN82  

AZ Finance LLC

USD 1,100 03-Mar-23 03-Mar-28 4.875% Semi-annual US04636NAF06  

AZ PLC

EUR 800 12-May-16 12-May-28 1.25% Annual XS1411404426 2

AZ Finance LLC

USD 1,250 28-May-21 28-May-28 1.75% Semi-annual US04636NAE31  

AZ PLC

USD 1,000 17-Aug-18 17-Jan-29 4.00% Semi-annual US046353AT52  

AZ Finance LLC

USD 1,250 26-Feb-24 26-Feb-29 4.85% Semi-annual US04636NAL73  

AZ PLC

EUR 800 03-Jun-21 03-Jun-29 0.375% Annual XS2347663507 3

AZ Finance LLC

USD 650 03-Mar-23 03-Mar-30 4.90% Semi-annual US04636NAG88  
AZ Finance LLC EUR 650 05-Aug-24 05-Aug-30 3.121% Annual XS2872909697 4

AZ PLC

USD 1,300 06-Aug-20 06-Aug-30 1.375% Semi-annual US046353AW81  

AZ Finance LLC

USD 1,000 26-Feb-24 26-Feb-31 4.90% Semi-annual US04636NAM56  

AZ Finance LLC

USD 750 28-May-21 28-May-31 2.25% Semi-annual US04636NAB91  

AZ PLC

GBP 350 13-Nov-07 13-Nov-31 5.75% Annual XS0330497149 3

AZ PLC

EUR 750 03-Mar-23 03-Mar-32 3.75% Annual XS2593105476 5

AZ Finance LLC

USD 500 03-Mar-23 03-Mar-33 4.875% Semi-annual US04636NAH61  
AZ Finance LLC EUR 750 05-Aug-24 05-Aug-33 3.278% Annual XS2872909770 6

AZ Finance LLC

USD 1,500 26-Feb-24 26-Feb-34 5.00% Semi-annual US04636NAN30  

AZ PLC

USD 2,750 12-Sep-07 15-Sep-37 6.45% Semi-annual US046353AD01  

AZ PLC

USD 1,000 18-Sep-12 18-Sep-42 4.00% Semi-annual US046353AG32  

AZ PLC

USD 1,000 16-Nov-15 16-Nov-45 4.375% Semi-annual US046353AM00  

AZ PLC

USD 750 17-Aug-18 17-Aug-48 4.375% Semi-annual US046353AU26  

AZ PLC

USD 500 06-Aug-20 06-Aug-50 2.125% Semi-annual US046353AX64  

AZ PLC

USD 750 25-May-21 28-May-51 3.00% Semi-annual US046353AZ13  

 

1 Swapped to approximately USD 791m at approximately 4.91%, semi-annual payments

2 Swapped to approximately USD 912m at approximately 3.06%, semi-annual payments

3 In a net investment hedge relationship. For more details, please refer to note 28 of our Annual Report and Form 20-F Information 2023.

4 Swapped to approximately USD 704m at approximately SOFR + 0.80%, quarterly payments

5 Swapped to approximately USD 791m at approximately 4.83%, semi-annual payments

6 Swapped to approximately USD 812m at approximately SOFR + 0.95%, quarterly payments

Credit ratings

AstraZeneca PLC aims to maintain a strong, investment grade credit rating. The Company has solicited credit ratings from Moody’s and S&P, which are assigned as:

  Moody's
S&P
Short-term rating P-1 A-1
Long-term rating A2 A+
Outlook Positive Stable


Key contacts at the respective agencies are:

Moody’s

Analyst: Martin Hallmark

Phone: +44 20 7772 1953

S&P

Analyst: Paulina Grabowiec

Phone: +44 20 7176 7051

Treasury risk management policies

The Company operates with a centralised Treasury structure so that key Treasury risks are managed at a Group level.
 

Liquidity Policy

  • Prudent level of available cash and unutilised credit facilities
  • Group funding centrally managed
     

Investment policy

  • Security and liquidity
  • Financial counterparty limits
     

Foreign Exchange Policy

  • Foreign Exchange exposures managed centrally
  • Transactional currency exposures substantially hedged
     

Interest Rate Policy

  • Aim to broadly match level of floating rate debt to cash over time
  • Significant portion of financial liabilities at fixed interest rates
     

Credit Risk

  • Cash managed centrally
  • Derivatives positions predominately cash collateralised

Debt IR presentations

Press Releases

FMSB Statement of Commitment



Contact Us


Christer Gruvris

Director of Investor Relations

Jonathan Slade

Group Treasurer


  • Annual Reports

    Our Annual Report provides a wide range of information about our global business.


  • Our Pipeline

    Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development


  • Shareholder FAQs

    Answers to frequently asked shareholder questions.